Here we sought to examine whether the orphan receptor Gpr55 could be a genetic modifier and potential novel drug target in the Scn1a+/- mouse model of Dravet syndrome. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.